# A Trial Comparing the Efficacy and Safety of HR17031 Injection to INS068 Injection and to SHR20004 Injection in Patients With Type 2 Diabetes

Study · id `cardio:ct-nct05333835` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05333835](<https://clinicaltrials.gov/study/NCT05333835>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05333835

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 455 participants.

## Technical summary

Registry record NCT05333835. Randomized; no masking; primary purpose treatment. Start 2022-07-08 (actual); primary completion 2024-03-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 455 participants (enrolled count; ClinicalTrials.gov record NCT05333835, source copy `cardio:ctgov-nct05333835-2023-04-25`, retrieved 2026-10-26)
- Started: 2022-07-08 (actual) (ClinicalTrials.gov record NCT05333835, source copy `cardio:ctgov-nct05333835-2023-04-25`, retrieved 2026-10-26)
- Primary completion: 2024-03-30 (anticipated) (ClinicalTrials.gov record NCT05333835, source copy `cardio:ctgov-nct05333835-2023-04-25`, retrieved 2026-10-26)
- Completion: 2024-03-30 (anticipated) (ClinicalTrials.gov record NCT05333835, source copy `cardio:ctgov-nct05333835-2023-04-25`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05333835, source copy `cardio:ctgov-nct05333835-2023-04-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05333835-2023-04-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Trial Comparing the Efficacy and Safety of HR17031 Injection to INS068 Injection and to SHR20004 Injection in Patients With Type 2 Diabetes
- Condition: Type 2 Diabetes
- Intervention (Drug): HR17031 injection
- Intervention (Drug): INS068 injection
- Intervention (Drug): SHR20004 injection
- Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Jiangsu HengRui Medicine Co., Ltd. (`cardio:org-jiangsu-hengrui-medicine-co-ltd`)

## Provenance

Content hash: 21f35c30fed118a7c170a0970954144216d32b56556de78ccb485fe747fac309
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
